|Bid||1.1500 x 2200|
|Ask||1.3100 x 900|
|Day's Range||1.2100 - 1.3200|
|52 Week Range||0.5700 - 11.4300|
|Beta (3Y Monthly)||3.11|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 7, 2018 - May 11, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.00|
LIVONIA, Mich., March 15, 2019 -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for.
SAN DIEGO, Jan. 03, 2019 -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards.
A look at the shareholders of Gemphire Therapeutics Inc. (NASDAQ:GEMP) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, Read More...
Gemphire Therapeutics Inc. (GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and nonalcoholic steatohepatitis (NASH), today announced that its Board of Directors is conducting a review of a range of strategic alternatives focused on maximizing stockholder value. The Company has engaged Ladenburg Thalmann & Co. Inc. to act as its strategic financial advisor for this process. The Board of Directors has established a committee to oversee this review. Potential strategic alternatives that may be evaluated include, but are not limited to, an acquisition, merger, business combination, in-licensing, or other strategic transaction involving the Company. There can be no assurance that this process will result in Gemphire pursuing any transaction or that any transaction, if pursued, will be completed.
NEW YORK, Nov. 19, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
LIVONIA, Mich., Nov. 08, 2018 -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Sept. 25) Abbott Laboratories (NYSE: ABT ) Aldeyra Therapeutics ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 6) Bio-Rad Laboratories, Inc. (NYSE: BIO ) BIO-TECHNE Corp (NASDAQ: ...
On July 6, Gemphire Therapeutics (GEMP) stock closed at $8.09, ~70% higher than its 52-week low of $4.75 on May 7. After Gemphire announced positive clinical trial results on June 28, its stock price started to rise and closed at $5.24, and on June 29, it rose ~94.47% to $10.19.
Yesterday, Gemphire Therapeutics (GEMP) announced that its Phase 2b INDIGO-1 trial evaluating investigational first-in-class oral therapy, gemcabene, achieved its primary endpoint of significantly reducing triglyceride levels in Severe Hypertriglyceridemia (or SHTG) patients with baseline serum triglyceride levels greater than 500 mg/dl. The drug also demonstrated a solid safety and tolerability profile and could be safely combined with other drugs. Gemcabene currently holds a method patent in SHTG indication valid until 2032. ...
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Foot Locker, Inc. (NYSE: FL ) stock was trading higher ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 28) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Aptinyx Inc (NASDAQ: ...
NEW YORK, NY / ACCESSWIRE / June 29, 2018 / It was a huge day for Gemphire Therapeutics on Thursday, skyrocketing over 120% in after-hours trading on the announcement that the company had achieved its primary endpoint in its Phase 2b INDIGO-1 trial in SHTG in patients with baseline serum TGs 500 mg/dL. Shares of Teva Pharmaceuticals saw gains after announcing that the company would be presenting new data for its migraine drug Fremanezumab at the AHS's (American Headache Society) 60th Annual Scientific Meeting in San Francisco. Teva Pharmaceutical Industries Limited shares closed up 4.53% yesterday on roughly 14.8 million shares traded.
I am going to take a deep dive into Gemphire Therapeutics Inc’s (NASDAQ:GEMP) most recent ownership structure, not a frequent subject of discussion among individual investors. The impact of aRead More...